Acquired aplastic anemia

JAMA

Volumn 282, Issue 3, 1999, Pages 271-278

  Young, Neal S ^a,b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY;

ADULT; APLASTIC ANEMIA; ARTICLE; BONE MARROW DEPRESSION; CASE REPORT; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE COURSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033591901     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.3.271     Document Type: Article

References (57)

1. Ehrlich P. Ueber einem Fall von Anämie mit Bemerkungen über regenerative Veränderungen des Knochenmarks. Charité-Annalen. 1888;13:300-309.
2. Vaquez MH, Aubertin C. L'anémie pernicieuse d'après les conceptions actuelles. Bull Mem Soc Med Hop Paris. 1904;21:288-297.
3. Santesson CG. Über chronische Vergiftung mit Steinkohlentheerbenzin: vir Todesfälle. Arch Hyg Berl. 1897;31:336-376.
4. Sharpe WD. Benzene, artificial leather, and aplastic anemia: Newark, 1916-1928. Bull N Y Acad Med. 1993;69:47-60.
5. Lewis CN, Putnam LE, Hendricks FD, Kerlan I, Welch H. Chloramphenicol (chloromycetin) in relation to blood dyscrasias with observations on other drugs: a special study. Antibiotic Chemother. 1952;2:601-609.
6. The International Agranulocytosis and Aplastic Anemia Study. The Drug Etiology of Agranulocytosis and Aplastic Anemia. New York, NY: Oxford University Press; 1990.
7. Issaragrisil S, Leaverton PE, Chansung K, et al. The incidence of acquired aplastic anemia in rural Thailand. Am J Hematol. In press.
8. Chongli Y, Xiaobo Z. Incidence survey of aplastic anemia in China. Chin Med Sci J. 1991;6:203-207.
9. Ringer R. Carter-Wallace to halt research. New York Times. October 5, 1994:D4.
10. Camitta BM, Thomas D, Nathan DG, et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood. 1979;53:504-514.
11. Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood. 1995;85:3058-3065.
12. Maciejewski JP, Selleri C, Sato T, Anderson SA, Young NS. A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long term culture-initiating cells) in acquired aplastic anemia. Blood. 1996;88:1983-1991.
13. Ball SE, Gibson FM, Rizzo S, Tooze JA, Marsh JCW, Gordon-Smith EC. Progressive telomere shortening in aplastic anemia. Blood. 1998;91:3582-3592.
14. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med. 1997;336: 1365-1372.
15. Mathé G, Amiel JL, Schwarzenberg L, et al. Bone marrow graft in man after conditioning by antilymphocytic serum. BMJ. 1970;2:131-136.
16. Hinterberger W, Rowlings PA, Hinterberger-Fischer M, Gibson J. Results of transplanting bone marrow from genetically identical twins into patients with aplastic anemia. Ann Intern Med. 1997;126:116-122.
17. Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med. 1990;323:315-321.
18. Marmont AM. The graft versus leukemia (GVL) effect after allogeneic bone marrow transplantation for chronic myelogeound leukemia. Leuk Lymphoma. 1993;11(suppl 1):221-226.
19. Sloand E, Kim S, Maciejewski JP, Chaudhuri A, Kirby M, Young NS. Presence of intracellular interferon-gamma (IFN-gamma) in circulating lymphocytes and response to immunosuppressive therapy in patients with aplastic anemia [abstract]. Blood. 1998;92 (suppl 1):158.
20. Wolk A, Simon-Stoos K, Nami I, et al. A mouse model of immune-mediated aplastic anemia [abstract]. Blood. 1998;10(suppl 1):158-159.
21. Brown KE, Tisdale J, Dunbar CE, Young NS. Hepatitis-associated aplastic anemia. N Engl J Med. 1997; 336:1059-1064.
22. Nimer SD, Ireland P, Meshkinpour A, Frane M. An increased HLA DR2 frequency is seen in aplastic anemia patients. Blood. 1994;84:923-927.
23. Nakao S, Takamatsu H, Chuhjo T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood. 1994;84:4257-4261.
24. Gerson WT, Fine DG, Spielberg SP, Sensenbrenner LL. Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro. Blood. 1983;61:889-893.
25. Young NS, Barrett AJ. The treatment of severe acquired aplastic anemia. Blood. 1995;85:3367-3377.
26. Tsai TW, Freytes CO. Allogeneic bone marrow transplantation for leukemias and aplastic anemia. Adv Intern Med. 1997;42:423-451.
27. Storb R, Etzioni R, Anasetti C, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994;84:941-949.
28. Bacigalupo A, Brand R, Sodé G, et al. Bone marrow transplantation (BMT) or immunosuppressive therapy (IS) for severe aplastic anemia (SAA). Semin Hematol. In press.
29. Bacigalupo A. Treatment of severe aplastic anaemia. In: Gordon-Smith EC, ed. Aplastic Anaemia: Clinical Haematology. Vol 2. London, England: Bailliere Tindall; 1989:19-36.
30. Deeg HJ, Leisenring W, Storb R, et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood. 1998;91:3637-3645.
31. Champlin RE, Horowitz MM, vanBekkum DW, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood. 1989;73:606-613.
32. Margolis D, Camitta B, Pietryga D, Keever-Taylor C. Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults. Br J Haematol. 1996;94:65-72.
33. Keman NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993;328:593-602.
34. Bacigalupo A. Severe Aplastic Anaemia Working Party. In: EBMT Working Parties Reports. Harrogate, England: European Group for Bone Marrow Transplantation; 1994:49-62.
35. Witherspoon RP, Fisher LD, Schock G, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med. 1989;321: 784-789.
36. Socié G, Henry-Amar M, Cosset JM, Devergie A, Girinsky T, Gluckman E. Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia. Blood. 1991;78:277-279.
37. Curtis ER, Rowlings PA, Deeg J, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897-904.
38. Bacigalupo A, Broccia G, Corda G, et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA working party. Blood. 1995;85:1348-1353.
39. Raghavachar A, Kolbe K, Höffken K, et al. A randomized trial of standard immunosuppression versus cyclosporine and filgastrim in severe aplastic anemia [abstract]. Blood. 1997;90(suppl 1):439.
40. Bielory L, Lawley T, Gascon P, Yancey K, Young N, Frank MM. Human serum sickness after equine antithymocyte globulin in patients with bone marrow failure. Medicine. 1988;67:40-57.
41. Bacigalupo A, Brand R, Socie G, et al. Bone marrow transplantation (BMT) or immunosuppressive therapy (IS) for patients with severe aplastic anemia (SAA): a report of the European Group for Blood and Marrow Transplantation (EBMT) [abstract]. Blood. 1998;92(suppl 1):158.
42. Genestier L, Foumel S, Flacher M, Assossou O, Revillard JP, Bonnefoy-Berard N. Induction of Fas (Apo-, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulin. Blood. 1998;91:2360-2368.
43. Merion RM, Howell T, Bromberg JS. Partial T-cell activation and anergy induction by polyclonal antithymocyte globulin. Transplantation. 1998;65:1481-1489.
44. Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Blood. 1996:87:491-494.
45. Gardner FH, Juneja HS. Androstane therapy to treat aplastic anaemia in adults: an uncontrolled pilot study. Br J Haematol. 1987;65:295-300.
46. Najean Y, Haguenauer O. Long-term (5 to 20 years) evolution of nongrafted aplastic anemia. Blood. 1990;76:2222-2228.
47. Marsh JCW, Socié G, Schrezenmeier H, et al. Haemopoietic growth factors in aplastic anaemia: a cautionary note. Lancet. 1994;344:172-173.
48. Gluckman E, Rokicka-Milewska R, Gordon-Smith EC, et al. Results of a randomized study of glycosylated rHuG-CSF Lenogastrim in severe aplastic anemia [abstract]. Blood. 1998;92(suppl 1):376.
49. Kojima S, Matsuyama T. Stimulation of granulopoiesis by high-dose recombinant human granulocyte colony-stimulating factor in children with aplastic anemia and very severe neutropenia. Blood. 1994; 83:1474-1478.
50. Bessho M, Hirashima K, Asano S, Ikeda Y, for the Multicenter Study Group. Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled study. Eur J Haematol. 1997;58:265-272.
51. Kurzrock R, Paquette R, Gratwohl A, et al. Use of stem cell factor (Stemgen, SCF) and filgastrim (GCSF) in aplastic anemia (AA) patients who have failed ATG/ ALG therapy [abstract]. Blood. 1997;90(suppl 1):173.
52. Imashuku S, Hibi S, Mitsui T, et al. A review of 125 cases to determine the risk of myelodysplasia and leukemia in pediatric neutropenic patients after treatment with recombinant human granulocyte colony-stimulating factor. Blood. 1996;84:2380-2381.
53. Kaito K, Kobayashi M, Katayama T, et al. Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults. Br J Haematol. 1998;103:297-303.
54. Socié G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med. 1993;329:1152-1157.
55. Dunn DE, Tanawattanacharoen P, Boccuni P, et al. Paroxysmal nocturnal hemoglobinuria populations in patients with bone marrow failure: prevalence, progression, and relationship to immunosuppressive therapy [abstract]. Blood. 1998;92(suppl 1):15.
56. Molldrem J, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin (ATG) abrogates cytopenias in patients with myelodysplastic syndrome. Br J Haematol. 1997;99:699-705.
57. Killick SB, Win N, Marsh JCW, et al. Pilot study of HLA alloimmunization after transfusion with prestorage leucodepleted blood products in aplastic anemia. Br J Haematol. 1997;97:677-684.